Below are the most recent publications written about "Janus Kinase 2" by people in Profiles.
-
Zhan X, Xiao H, Wang Q, Luo J, Ma L, Zhang X, Tang J, Meng X. Natural killer cell nano-engagers drive ferroptosis-immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis. J Control Release. 2026 Feb 10; 390:114581.
-
Koerber RM, Krollmann C, Cieslak K, Tregel E, Saenz ML, Br?mmendorf TH, Koschmieder S, Griesshammer M, G?tgemann I, Baldauf CK, Fischer T, Brossart P, Kolbe CC, Latz E, Wolf D, Teichmann LL. NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms. Nat Commun. 2025 Nov 26; 16(1):10591.
-
Shan Y, DeSouza N, Littman N, Qiu Q, Nguyen K, Yu Y, Mohi G, Li S. A blockade of leukotriene-mediated Alox5 function provides a new strategy for the treatment of JAK2V617F-induced polycythemia vera. Haematologica. 2025 Nov 01; 110(11):2702-2713.
-
Li D, DeSouza N, Nguyen K, Li S. Leukaemia Stem Cells and Their Normal Stem Cell Counterparts Are Morphologically Distinguishable by Artificial Intelligence. J Cell Mol Med. 2025 May; 29(10):e70564.
-
Kohal R, Bisht P, Gupta GD, Verma SK. Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations. Bioorg Chem. 2024 02; 143:107095.
-
Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 10 20; 387(16):1445-1455.
-
Yan B, Freiwald T, Chauss D, Wang L, West E, Mirabelli C, Zhang CJ, Nichols EM, Malik N, Gregory R, Bantscheff M, Ghidelli-Disse S, Kolev M, Frum T, Spence JR, Sexton JZ, Alysandratos KD, Kotton DN, Pittaluga S, Bibby J, Niyonzima N, Olson MR, Kordasti S, Portilla D, Wobus CE, Laurence A, Lionakis MS, Kemper C, Afzali B, Kazemian M. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci Immunol. 2021 04 07; 6(58).
-
Kay J, Harigai M, Rancourt J, Dickson C, Melby T, Issa M, de la Torre I, Isaka Y, Cardoso A, Saifan C, Keystone EC, van Vollenhoven RF, Giles JT, Huizinga TW, Kremer JM. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020 10; 6(3).
-
Wang JC, Chen C, Kundra A, Kodali S, Pandey A, Wong C, Cheung T, Gotlieb V, Joseph G, Tribie S. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res. 2019 04; 79:52-59.
-
Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024.